China Biologic Products to Report Third Quarter 2019 Financial Results

BEIJING,Nov. 4,2019 -- China Biologic Products Holdings,Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"),a leading fully integrated plasma-based biopharmaceutical company inChina,today announced that the Company plans to release its third quarter 2019 financial results onWednesday,November 13,2019after the market closes.

The Company's management will hold a conference call at7:30 a.m. ETonThursday,November 14,2019,which is8:30 p.m.Beijing Time onNovember 14,to discuss third quarter 2019 results. Listeners may access the call by dialing:

US:

1 888 346 8982

International:

1 412 902 4272

Hong Kong:

800 905945

China:

4001 201203

A telephone replay will be available one hour after the conclusion of the conference call throughNovember 21,2019. The dial-in details are:

US:

1 877 344 7529

International:

1 412 317 0088

Passcode:

10136730

A live and archived webcast of the conference call will be available through the Company's investor relations website athttp://chinabiologic.investorroom.com/.

About China Biologic Products Holdings,Inc.

China Biologic Products Holdings,Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company inChina. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered inBeijingand manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary,Shandong Taibang Biological Products Co.,Ltd. and its wholly owned subsidiary,Guizhou Taibang Biological Products Co.,Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co.,Ltd. Since the acquisition of TianXinFu (Beijing) Medical Appliance Co.,Ltd. in 2018,China Biologic is also engaged in the manufacturing and sale of medical devices,primarily regenerative medical biomaterial products. The Company sells its products to hospitals,distributors and other healthcare facilities inChina. For additional information,please see the Company's websitewww.chinabiologic.com.

Contact:

China Biologic Products Holdings,Inc.

Mr.Ming Yin

Senior Vice President

Email:ir@chinabiologic.com

The Foote Group

Mr.Philip Lisio

Phone: +86-135-0116-6560

E-mail:phil@thefootegroup.com

View original content:/news-releases/china-biologic-products-to-report-third-quarter-2019-financial-results-300950604.html